comparemela.com

Latest Breaking News On - Secondary progressive multiple sclerosis - Page 13 : comparemela.com

Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients

26.10.2022 - NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the .

Tiziana Life Sciences Ltd starts enrollment of first patient cohort in program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patients

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the start of enrollment of the first patient cohort in its intermediate-size patient population.

AB Science today reports its revenues for the first half of

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.